Cartesian CMO sells shares to cover tax withholding

Cartesian Therapeutics Chief Medical Officer Milos Miljkovic reported a small sale of company stock tied to equity compensation taxes.

Rhea-AI Filing Summary

Cartesian Therapeutics Chief Medical Officer Milos Miljkovic reported a small sale of company stock tied to equity compensation taxes. On 01/06/2026, he sold 3,573 shares of Cartesian Therapeutics, Inc. common stock at a price of $6.8197 per share. According to the footnote, the shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees, rather than as a discretionary open-market sale. After this transaction, he continued to beneficially own 58,820 shares of common stock in direct ownership.

Insights

Equity compensation and insider activity analyst

Routine tax-withholding sale tied to RSU vesting, limited size.

The reporting person, Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics, Inc., disclosed the sale of 3,573 shares of common stock on 01/06/2026 at $6.8197 per share. The filing states that these shares were sold to satisfy withholding tax obligations triggered by the vesting of restricted stock units and to cover related broker fees.

Because the transaction is explicitly linked to RSU tax withholding rather than a discretionary portfolio decision, it represents a standard mechanism for handling taxes on equity awards. After the sale, Miljkovic still beneficially owned 58,820 shares directly, indicating continued equity exposure to the company. The filing describes a single non-derivative transaction and no changes to derivative holdings.

Insider Trade Summary

Net Seller: 3,573 shares

Net Sell 1 txn

Insider Miljkovic Milos

Role Chief Medical Officer

Sold 3,573 shs ($24K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,573	$6.8197	$24K

Holdings After Transaction: Common Stock — 58,820 shares (Direct)

Footnotes (1)

1. F1. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RNAC report in this Form 4 filing?

The filing reports that Chief Medical Officer Milos Miljkovic sold 3,573 shares of Cartesian Therapeutics, Inc. common stock on 01/06/2026.

At what price did Milos Miljkovic sell Cartesian Therapeutics (RNAC) shares?

He sold 3,573 shares of Cartesian Therapeutics common stock at a price of $6.8197 per share.

Why were the RNAC shares sold by Chief Medical Officer Milos Miljkovic?

According to the footnote, the shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

How many Cartesian Therapeutics (RNAC) shares does Milos Miljkovic own after this transaction?

Following the reported sale, Milos Miljkovic beneficially owned 58,820 shares of Cartesian Therapeutics common stock in direct ownership.

Is the Milos Miljkovic Form 4 transaction a direct or indirect ownership change?

The Form 4 indicates that the transaction involved direct (D) ownership of Cartesian Therapeutics common stock by Milos Miljkovic.

What is the role of Milos Miljkovic at Cartesian Therapeutics (RNAC)?

The filing identifies Milos Miljkovic as an officer of Cartesian Therapeutics, Inc., serving as the company’s Chief Medical Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miljkovic Milos

(Last) (First) (Middle)

C/O CARTESIAN THERAPEUTICS, INC.

7495 NEW HORIZON WAY

(Street)

FREDERICK MD 21703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cartesian Therapeutics, Inc. [ RNAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S		3,573	D	$6.8197(1)	58,820	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

Remarks:

	/s/ Matthew Bartholomae, Attorney-in-Fact for Milos Miljkovic	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.